Subcutaneous low doses of interleukin-2 and recombinant interferon alpha with carboplatin and vinblastine in patients with advanced melanoma

Απλή σελίδα τεκμηρίου
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorBakoyiannis, C.en
dc.contributor.authorKarvounis, N.en
dc.contributor.authorKosmidis, P.en
dc.date.accessioned2015-11-24T18:50:05Z
dc.date.available2015-11-24T18:50:05Z
dc.identifier.issn0030-2414-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18033
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Agents, Phytogenic/administration & dosageen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectCarboplatin/administration & dosageen
dc.subjectChemotherapy, Adjuvanten
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectInjections, Subcutaneousen
dc.subjectInterferon-alpha/administration & dosageen
dc.subjectInterleukin-2/administration & dosageen
dc.subjectMaleen
dc.subjectMelanoma/*drug therapy/secondaryen
dc.subjectMiddle Ageden
dc.subjectProspective Studiesen
dc.subjectSkin Neoplasms/*drug therapy/pathologyen
dc.subjectSurvival Analysisen
dc.subjectTreatment Outcomeen
dc.subjectVinblastine/administration & dosageen
dc.titleSubcutaneous low doses of interleukin-2 and recombinant interferon alpha with carboplatin and vinblastine in patients with advanced melanomaen
heal.abstractTwenty-three patients with advanced melanoma were treated with a combination of subcutaneous recombinant human interleukin-2 (IL-2), and recombinant interferon alpha-2a (IFN-alpha) with chemotherapy consisting of four cycles of carboplatin (300 mg/m2, day 1) and vinblastine (6 mg/m2, day 1), every 28 days (CV-IL-IF). IL-2 was given at a dose of 4.5 x 10(6) U twice daily on days 3-6 and days 21-24 of each cycle; IFN-alpha dose was 4.5 x 10(6) U, starting on day 2, thrice weekly. Immunotherapy was intended to continue for 6 months. Of the 23 analyzed patients, 4 (17%) achieved an objective response, including 1 complete and 3 partial responses, in nonvisceral metastatic disease. The median time to progression was 5 months and the median survival from onset of the treatment 6 months (range 1-14 months). Four patients discontinued the treatment, due to nonhaematologic toxicity; 3 for severe weakness and the 4th patient for long-lasting CNS side-effects. Other grade 3-4 toxicities included weight loss (22%), nausea and vomiting (17%) and alopecia (13%). The haematologic toxicity was acceptable. No toxic death was noted. It is concluded that the CV-IL-IF regimen has limited activity and moderate toxicity.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9428375-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000011834-
heal.journalNameOncologyen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1998-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ